Hudson Bay Capital Management
LRMR icon

Hudson Bay Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Hudson Bay Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-377,000
Closed -$1.22M – 1391
2025
Q3 		$1.22M Buy
+377,000
New +$1.41M ﹤0.01% 832

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Hudson Bay Capital Management's LRMR Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Larimar Therapeutics (LRMR) stake by 96% in Q2 2026, selling an estimated $1.12M and leaving 11,000 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1264.

Hudson Bay Capital Management first reported a position in LRMR in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.32M in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Hudson Bay Capital Management held 11,000 shares of Larimar Therapeutics worth $33.5K as of Q2 2026.
  • Hudson Bay Capital Management sold 281,250 Larimar Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Larimar Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #1264 holding.
  • Hudson Bay Capital Management first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Hudson Bay Capital Management's Larimar Therapeutics position peaked at $1.32M in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.